Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Australian Clinical Labs Ltd ( (AU:ACL) ) is now available.
Australian Clinical Labs Ltd has announced the appointment of Stephen Roche as a director, effective from June 20, 2025. The announcement indicates that Roche currently holds no relevant interests in securities, suggesting a fresh start in his role, which may impact the company’s governance and strategic direction.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, primarily focusing on providing pathology services. The company is involved in medical testing and diagnostics, catering to a wide range of healthcare needs.
Average Trading Volume: 922,127
Technical Sentiment Signal: Sell
Current Market Cap: A$538.1M
See more data about ACL stock on TipRanks’ Stock Analysis page.